Abstract
SCH23390 is a widely used D1 dopamine receptor (D1R) antagonist that also elicits some D1R-independent effects. We previously found that the benzazepine, SKF83959, an analog of SCH23390, produces positive allosteric modulation of the Sigma-1 receptor (Sig1R). SCH23390 does not bind to the orthodoxic site of Sig1R but enhances the binding of 3H (+)-pentazocine to Sig1R. In this study, we investigated whether SCH23390 functions as an allosteric modulator of Sig1R. We detected increased Sig1R dissociation from binding immunoglobulin protein (BiP) and translocation of Sig1R to the plasma membrane in response to SCH23390 in transfected HEK293T and SH-SY5Y cells, respectively. Activation of Sig1R by SCH23390 was further confirmed by inhibition of GSK3β activity in a time- and dose-dependent manner; this effect was blocked by pretreatment with the Sig1R antagonist, BD1047, and by knockdown of Sig1R. SCH23390 also inhibited GSK3β in wild-type mice but not in Sig1R knockout mice. Finally, we showed that SCH23390 allosterically modulated the effect of the Sig1R agonist SKF10047 on inhibition of GSK3β. This positive allosteric effect of SCH23390 was further confirmed via promotion of neuronal protection afforded by SKF10047 in primary cortical neurons challenged with MPP+. These results provide the first evidence that SCH23390 elicits functional allosteric modulation of Sig1R. Our findings not only reveal novel pharmacological effects of SCH23390 but also indicate a potential mechanism for SCH23390-mediated D1R-independent effects. Therefore, attention should be paid to these Sig1R-mediated effects when explaining pharmacological responses to SCH23390.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bourne JA. SCH 23390: the first selective dopamine D1-like receptor antagonist. CNS Drug Rev. 2001;7:399–414.
Waddington JL, O’Boyle KM. Drugs acting on brain dopamine receptors: a conceptual re-evaluation five years after the first selective D1 antagonist. Pharmacol Ther. 1989;43:1–52.
Arnsten AF, Cai JX, Murphy BL, Goldman-Rakic PS. Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology (Berl). 1994;116:143–51.
Kempadoo KA, Mosharov EV, Choi SJ, Sulzer D, Kandel ER. Dopamine release from the locus coeruleus to the dorsal hippocampus promotes spatial learning and memory. Proc Natl Acad Sci USA. 2016;113:14835–40.
Puig MV, Antzoulatos EG, Miller EK. Prefrontal dopamine in associative learning and memory. Neuroscience. 2014;282:217–29.
Tanyeri P, Buyukokuroglu ME, Mutlu O, Ulak G, Akar FY, Celikyurt IK, et al. Effects of ziprasidone, SCH23390 and SB277011 on spatial memory in the Morris water maze test in naive and MK-801 treated mice. Pharmacol Biochem Behav. 2015;138:142–7.
Tao YM, Yu C, Wang WS, Hou YY, Xu XJ, Chi ZQ, et al. Heteromers of mu opioid and dopamine D1 receptors modulate opioid-induced locomotor sensitization in a dopamine-independent manner. Br J Pharmacol. 2017;174:2842–61.
Nesbit MO, Chai A, Axerio-Cilies P, Phillips AG, Wang YT, Held K. The selective dopamine D1 receptor agonist SKF81297 modulates NMDA receptor currents independently of D1 receptors. Neuropharmacology. 2022;207:108967.
Yu Y, Wang JR, Sun PH, Guo Y, Zhang ZJ, Jin GZ, et al. Neuroprotective effects of atypical D1 receptor agonist SKF83959 are mediated via D1 receptor-dependent inhibition of glycogen synthase kinase-3 beta and a receptor-independent anti-oxidative action. J Neurochem. 2008;104:946–56.
Guo L, Zhao J, Jin G, Zhao B, Wang G, Zhang A, et al. SKF83959 is a potent allosteric modulator of sigma-1 receptor. Mol Pharmacol. 2013;83:577–86.
Fukunaga K, Moriguchi S. Stimulation of the sigma-1 receptor and the effects on neurogenesis and depressive behaviors in mice. Adv Exp Med Biol. 2017;964:201–11.
Hashimoto K. Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication. J Pharmacol Sci. 2015;127:6–9.
Wang Y, Guo L, Jiang HF, Zheng LT, Zhang A, Zhen XC. Allosteric modulation of sigma-1 receptors elicits rapid antidepressant activity. CNS Neurosci Ther. 2016;22:368–77.
Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol. 2020;18:e3000410.
Zhang G, Chen S, Jia J, Liu C, Wang W, Zhang H, et al. Development and evaluation of novel metformin derivative metformin threonate for brain ischemia treatment. Front Pharmacol. 2022;13:879690.
Zhang G, Li Q, Tao W, Qin P, Chen J, Yang H, et al. Sigma-1 receptor-regulated efferocytosis by infiltrating circulating macrophages/microglial cells protects against neuronal impairments and promotes functional recovery in cerebral ischemic stroke. Theranostics. 2023;13:543–59.
Wang M, Wan C, He T, Han C, Zhu K, Waddington JL, et al. Sigma-1 receptor regulates mitophagy in dopaminergic neurons and contributes to dopaminergic protection. Neuropharmacology. 2021;196:108360.
Lasbleiz C, Peyrel A, Tarot P, Sarniguet J, Crouzier L, Cubedo N, et al. Sigma-1 receptor agonist PRE-084 confers protection against TAR DNA-binding protein-43 toxicity through NRF2 signalling. Redox Biol. 2022;58:102542.
Yano H, Bonifazi A, Xu M, Guthrie DA, Schneck SN, Abramyan AM, et al. Pharmacological profiling of sigma 1 receptor ligands by novel receptor homomer assays. Neuropharmacology. 2018;133:264–75.
Huang W, Zuo W, Chen L, Wang L, Tewfik G, Fu R, et al. Acetaldehyde excitation of lateral habenular neurons via multiple cellular mechanisms. J Neurosci. 2021;41:7532–45.
Calvo B, Fernandez M, Rincon M, Tranque P. GSK3beta inhibition by phosphorylation at Ser(389) controls neuroinflammation. Int J Mol Sci. 2022;24:337.
Yan N, Xie F, Tang LQ, Wang DF, Li X, Liu C, et al. Synthesis and biological evaluation of thieno[3,2-c]pyrazol-3-amine derivatives as potent glycogen synthase kinase 3beta inhibitors for Alzheimer’s disease. Bioorg Chem. 2023;138:106663.
Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, McGrath JC, et al. The concise guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol. 2013;170:1449–58.
Alon A, Schmidt HR, Wood MD, Sahn JJ, Martin SF, Kruse AC. Identification of the gene that codes for the sigma(2) receptor. Proc Natl Acad Sci USA. 2017;114:7160–5.
Haller JL, Panyutin I, Chaudhry A, Zeng C, Mach RH, Frank JA. Sigma-2 receptor as potential indicator of stem cell differentiation. Mol Imaging Biol. 2012;14:325–35.
Hellewell SB, Bruce A, Feinstein G, Orringer J, Williams W, Bowen WD. Rat liver and kidney contain high densities of sigma 1 and sigma 2 receptors: characterization by ligand binding and photoaffinity labeling. Eur J Pharmacol. 1994;268:9–18.
Quirion R, Bowen WD, Itzhak Y, Junien JL, Musacchio JM, Rothman RB, et al. A proposal for the classification of sigma binding sites. Trends Pharmacol Sci. 1992;13:85–6.
Chen AF, Ma WH, Xie XY, Huang YS. Sigma-2 receptor as a potential drug target. Curr Med Chem. 2021;28:4172–89.
Riad A, Lengyel-Zhand Z, Zeng C, Weng CC, Lee VM, Trojanowski JQ, et al. The sigma-2 receptor/TMEM97, PGRMC1, and LDL receptor complex are responsible for the cellular uptake of Abeta42 and its protein aggregates. Mol Neurobiol. 2020;57:3803–13.
Vavers E, Zvejniece L, Dambrova M. Sigma-1 receptor and seizures. Pharmacol Res. 2023;191:106771.
Ye N, Qin W, Tian S, Xu Q, Wold EA, Zhou J, et al. Small molecules selectively targeting sigma-1 receptor for the treatment of neurological diseases. J Med Chem. 2020;63:15187–217.
Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival. Cell. 2007;131:596–610.
Maurice T. Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders. Expert Opin Drug Discov. 2021;16:373–89.
Crouzier L, Couly S, Roques C, Peter C, Belkhiter R, Arguel Jacquemin M, et al. Sigma-1 (sigma(1)) receptor activity is necessary for physiological brain plasticity in mice. Eur Neuropsychopharmacol. 2020;39:29–45.
Jia J, Cheng J, Wang C, Zhen X. Sigma-1 receptor-modulated neuroinflammation in neurological diseases. Front Cell Neurosci. 2018;12:314.
Ryskamp DA, Korban S, Zhemkov V, Kraskovskaya N, Bezprozvanny I. Neuronal sigma-1 receptors: signaling functions and protective roles in neurodegenerative diseases. Front Neurosci. 2019;13:862.
Su TP, Su TC, Nakamura Y, Tsai SY. The sigma-1 receptor as a pluripotent modulator in living systems. Trends Pharmacol Sci. 2016;37:262–78.
Vavers E, Zvejniece L, Maurice T, Dambrova M. Allosteric modulators of sigma-1 receptor: a review. Front Pharmacol. 2019;10:223.
Guo L, Chen Y, Zhao R, Wang G, Friedman E, Zhang A, et al. Allosteric modulation of sigma-1 receptors elicits anti-seizure activities. Br J Pharmacol. 2015;172:4052–65.
Zvejniece L, Vavers E, Svalbe B, Vilskersts R, Domracheva I, Vorona M, et al. The cognition-enhancing activity of E1R, a novel positive allosteric modulator of sigma-1 receptors. Br J Pharmacol. 2014;171:761–71.
Wu Z, Li L, Zheng LT, Xu Z, Guo L, Zhen X. Allosteric modulation of sigma-1 receptors by SKF83959 inhibits microglia-mediated inflammation. J Neurochem. 2015;134:904–14.
Scerbina T, Chatterjee D, Gerlai R. Dopamine receptor antagonism disrupts social preference in zebrafish: a strain comparison study. Amino Acids. 2012;43:2059–72.
Acknowledgements
This work was supported by the National Key Research and Development Program of China (2021YFE0206000), STI2030-Major Projects (2021ZD0204004), the National Natural Science Foundation of China (81973334, 81773702, 82003769). Support from Suzhou Gusu Health Talent Scientific Research Project (GSWS2021053) is also appreciated.
Author information
Authors and Affiliations
Contributions
GFZ, KLZ, QL and YZ performed experiments and data analysis; GFZ and KLZ analyzed the data and wrote the original draft; JLW and XDD reviewed the manuscript and developed the results and conclusions; XCZ designed the study and reviewed the manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Zhang, Gf., Zhu, Kl., Li, Q. et al. The classical D1 dopamine receptor antagonist SCH23390 is a functional sigma-1 receptor allosteric modulator. Acta Pharmacol Sin (2024). https://doi.org/10.1038/s41401-024-01256-1
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41401-024-01256-1